Spotlight on AMIGO2 as a novel prognostic indicator in pancreatic cancer

Pancreatic adenocarcinoma (PAAD) remains one of the most lethal cancers globally, with 510,992 new cases for both sexes across all ages, and ranks 12^th by cancer site (1,2). The mortality rate stands on 467,409 deaths, ranking 6^th when compared to all other types of cancer (3), and marked by a dismal 5-year survival rate and a propensity for silent progression until metastasis, limiting curative interventions.

It is imperative to provide either an early detection system, or to dramatically improve tumor prognosis for PAAD. Consequently, in such a challenging clinical terrain, identifying robust prognostic markers is of critical value. Much attention is focused on PAAD, and very recently a comprehensive review regarding the abundant types of biomarkers was published (4), highlighting the rapid advance in this area with the use of OMICS and artificial intelligence.

Protein-based (5-8) and RNA-based (9-12) biomarkers are among the most studied. Moreover, the sampling of blood and body fluids facilitates collection from patients for analyzing most types of disease (13,14). The work by Cao et al., titled “Comprehensive analysis identifies adhesion molecule with Ig-like domain 2 (AMIGO2) as a potential prognostic biomarker and a potential therapeutic target for pancreatic adenocarcinoma” is a timely and important addition to the field, offering novel insights into AMIGO2’s multifaceted role in tumor biology (15). AMIGO2, initially characterized for its role in neural development (16), has since been implicated in various malignancies (17). Currently, the authors hypothesize that AMIGO2 might serve as both a prognostic biomarker and a functional driver in pancreatic tumorigenesis (15). Through secondary data/integrative analyses encompassing multi-omics datasets, clinical annotations, immune profiling, and experimental validation, they established AMIGO2 as a dual-purpose marker: one predictive of disease outcome and also being of potential implementation in therapeutic contexts.

Multi-layered methodology reveals AMIGO2’s clinical relevance

The strength of this study lies in its layered analytical framework. Through utilizing The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, the team performed a secondary data analysis, demonstrating that AMIGO2 is significantly overexpressed in several malignancies, and notably in PAAD. Survival analyses revealed that patients with upregulated AMIGO2 expression have markedly poorer outcomes. Furthermore, multivariate Cox regression and nomogram modelling confirmed AMIGO2’s independent prognostic significance. Beyond statistical correlation, the authors validated their findings through functional assays. In vitro knockdown of AMIGO2 in PAAD cell lines led to reduced tumor proliferation and colony formation, underscoring its tumor-promoting capacity.

Molecular pathways: AMIGO2 and canonical oncogenic drivers

Cao et al. analysed possible AMIGO2’s intersection with key molecular pathways. Upregulated AMIGO2 expression correlated with Kirsten rat sarcoma viral oncogene homolog (KRAS) and transformation-related protein 53 (TP53) mutations—two of the most frequently mutated genes in PAAD (18,19). Gene set enrichment analysis (GSEA) highlighted enrichment in mitogen-activated protein kinase (MAPK) and p53 signaling pathways, as well as transforming growth factor-beta (TGF-β), adherens junctions, and cell cycle regulation. These findings suggest that AMIGO2 could act as a signaling integrator within these canonical cancer pathways.

Immune microenvironment and AMIGO2: implications for immunotherapy

Understanding the tumor microenvironment (TME) is crucial in this present era of immunotherapy. Chen et al. were the first to reveal that upregulated AMIGO2 expression in PAAD was associated with the polarization of immunosuppressive M2 macrophages (20), and confirmed that patients with upregulated AMIGO2 expression resulted in lower survival outcomes. Cao et al. further confirmed such points through immune infiltration and single-cell RNA sequencing analyses of TME. Moreover, they revealed that upregulated AMIGO2 expression is associated with increased infiltration of cancer-associated fibroblasts (15). AMIGO2-high tumors exhibited reduced cytolytic activity, reduced type II interferon responses, and upregulated expression of immune checkpoints, including programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), and lymphocyte-activation gene 3 (LAG3). These observations imply that AMIGO2 could serve as a marker of immune evasion, with potential utility in predicting response to immune checkpoint inhibitors. It opens the door to novel combinatorial strategies that pair anti-AMIGO2 agents with currently available PD-1/PD-L1 blockade therapeutic agents.

Pharmacogenomic insights: toward precision oncology

Pharmacological profiling revealed that AMIGO2-high tumors are more sensitive to BI-2536, a bromodomain containing 4 (BRD4) inhibitor, and resistant to cisplatin. This aligns with previous findings that BRD4 transcriptionally regulates AMIGO2 (21). These datasets point to AMIGO2 as not just being a passive biomarker, though it can also act as a targetable vulnerability in PAAD, supporting its inclusion in future precision oncology frameworks.

Model for translational oncology

This study shows a flow of translational research—from bioinformatics discovery, through experimental validation, to clinical implication. AMIGO2 is not only highlighted as a biomarker, but is also implicated in diverse tumorigenic processes, from metabolic dysregulation to immunosuppression and drug sensitivity. This positions it as a possible candidate for clinical translation.

Limitations and future directions

Despite its comprehensive approach, the study raises further questions regarding the potential of AMIGO2 as a biomarker and therapeutic target. Cao et al. focused principally on in vitro and computational analyses by strengthening previously published evidence (20,22-25). Nonetheless, until now, all studies are primarily in the preclinical or in the early validation stage, and there is no planned integration into in vivo and clinical functional studies, necessary to confirm the oncogenic role of AMIGO2 in PAAD. Regarding its potential as a biomarker, its usefulness should not only be compared with existing tumor markers such as Duke pancreatic monoclonal antigen type II (DUPAN-II) and carbohydrate antigen 19-9 (CA19-9), but also be clinically investigated as a predictive marker for selecting drug therapies in unresectable pancreatic cancer, in the context of resistance to anticancer drugs, as well as for predicting responses to immune checkpoint inhibitors, and for analysing its relevance to the TME. Additionally, its interplay with other immune regulatory molecules and its precise role within TME dynamics warrant deeper exploration, as well as better understanding of the pathways involved and mechanism. Clinical trials evaluating BRD4 inhibitors in AMIGO2-high patients would be a logical next step.

Conclusions

Cao et al.’s work adds significant depth to our understanding of pancreatic cancer biology. AMIGO2 emerges as a promising biomarker for poor prognosis and a potential therapeutic target. In a disease marked by limited options and poor outcomes, this study offers a path forward—a foundation upon which future therapeutic innovations can be built and improve both survival and quality of life of patients.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Gastrointestinal Oncology. The article did not undergo external peer review.

Funding: None.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2025-601/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2024.
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. [Crossref] [PubMed]
3. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer 2021; Epub ahead of print. [Crossref] [PubMed]
4. Murray K, Oldfield L, Stefanova I, et al. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. Semin Cancer Biol 2025;111:76-88. [Crossref] [PubMed]
5. Komura T, Takabatake H, Harada K, et al. Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma. Cancer Sci 2017;108:2122-9. [Crossref] [PubMed]
6. Nasti A, Inagaki S, Ho TTB, et al. Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer. Mol Oncol 2025;19:1452-70. [Crossref] [PubMed]
7. Nené NR, Ney A, Nazarenko T, et al. Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning. Commun Med (Lond) 2023;3:10. [Crossref] [PubMed]
8. Oldfield L, Evans A, Rao RG, et al. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBioMedicine 2022;75:103802. [Crossref] [PubMed]
9. Sakai Y, Honda M, Matsui S, et al. Development of novel diagnostic system for pancreatic cancer, including early stages, measuring mRNA of whole blood cells. Cancer Sci 2019;110:1364-88. [Crossref] [PubMed]
10. Nasti A, Miyazawa M, Seki A, et al. Bioinformatics Methods for the Identification of Treatment Response Prediction Markers in Pancreatic Cancer. In: New Trends in Intelligent Software Methodologies, Tools and Techniques. IOS Press; 2023:1-11.
11. Han Y, Drobisch P, Krüger A, et al. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma. J Hematol Oncol 2023;16:7. [Crossref] [PubMed]
12. Shu QA, Huang XD, Wu J, et al. ARHGAP11A is a potential prognostic biomarker and therapeutic target for pancreatic adenocarcinoma. Int J Biochem Cell Biol 2025;185:106804. [Crossref] [PubMed]
13. Sakai Y, Nasti A, Takeshita Y, et al. Eight-year longitudinal study of whole blood gene expression profiles in individuals undergoing long-term medical follow-up. Sci Rep 2021;11:16564. [Crossref] [PubMed]
14. Nasti A, Okumura M, Takeshita Y, et al. The declining insulinogenic index correlates with inflammation and metabolic dysregulation in non-obese individuals assessed by blood gene expression. Diabetes Res Clin Pract 2024;208:111090. [Crossref] [PubMed]
15. Cao J, Zhou T, Chen J, et al. Comprehensive analysis identifies AMIGO2 as a potential prognosis biomarker of pancreatic adenocarcinoma. J Gastrointest Oncol 2025;16:1287-304. [Crossref] [PubMed]
16. Ono T, Sekino-Suzuki N, Kikkawa Y, et al. Alivin 1, a novel neuronal activity-dependent gene, inhibits apoptosis and promotes survival of cerebellar granule neurons. J Neurosci 2003;23:5887-96. [Crossref] [PubMed]
17. Tian Z, Zhou D, Jiang R, et al. Role of AMIGO2 in cancer progression: Novel insights Oncol Lett 2024;28:434. (Review). [Crossref] [PubMed]
18. Yu J, Yan D, Liu X, et al. High-frequency KRAS mutations in pancreatic adenocarcinoma: prognostic significance and potential co-targeting therapies. Transl Cancer Res 2025;14:2331-42. [Crossref] [PubMed]
19. Basak U, Mukherjee S, Chakraborty S, et al. In-silico analysis unveiling the role of cancer stem cells in immunotherapy resistance of immune checkpoint-high pancreatic adenocarcinoma. Sci Rep 2025;15:10355. [Crossref] [PubMed]
20. Chen S, Du W, Feng K, et al. AMIGO2 is a pivotal therapeutic target related to M2 polarization of macrophages in pancreatic ductal adenocarcinoma. Aging (Albany NY) 2024;16:1111-27. [Crossref] [PubMed]
21. Fontanals-Cirera B, Hasson D, Vardabasso C, et al. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Mol Cell 2017;68:731-744.e9. [Crossref] [PubMed]
22. Mamoor S. Differential expression of AMIGO2 in pancreatic cancer. [Internet]. OSF; 2023 [cited 2025 Jul 24]. Available online: https://osf.io/a2wxe_v1
23. Jing Z, Feng FX. High Expression of AMIGO2 Is an Independent Predictor of Poor Prognosis in Pancreatic Cancer [Internet]. Research Square; 2021 [cited 2025 Jul 24]. Available online: https://www.researchsquare.com/article/rs-557347/v1 10.21203/rs.3.rs-557347/v110.21203/rs.3.rs-557347/v1
24. Yamaguchi N, Wu YG, Ravetch E, et al. A Targetable Secreted Neural Protein Drives Pancreatic Cancer Metastatic Colonization and HIF1α Nuclear Retention. Cancer Discov 2024;14:2489-508. [Crossref] [PubMed]
25. Nakamura T, Kuwai T, Kitadai Y, et al. Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res 2007;67:7597-604. [Crossref] [PubMed]